Neovascular glaucoma treated by intravitreal triamcinolone acetonide

Jonas, Jost B.; Kreissig, Ingrid; Degenring, Robert F.

doi:10.1034/j.1600-0420.2003.00130.x

Cited by 28 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering only the 4 patients for whom the intraocular cortisone injection was the only procedure performed, the mean intraocular pressure decreased from 26.5 ± 12.1 mm Hg to 21.75 ± 11.3 mm Hg. This report on the possible use of IVTA for adjunct treatment of neovascular glaucoma has been supported by recent investigations [112,114,115]. …”

Section: Clinical Studies: Ta In Other Ocular Diseasessupporting

confidence: 52%

“…IVTA has been discussed to be a possibly useful adjunct to the therapy of exudative AMD [116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152] since previous studies had shown that TA may have an antiangiogenic and antiedematous effect [112,113,114,115,258,259,260,262,263,264,265,266]. Both neovascularization and retinal edema are characteristics of exudative AMD.…”

Section: Clinical Studies: Ta In Other Ocular Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Intravitreal Triamcinolone

Tao

Jonas

2010

Ophthalmologica

Self Cite

View full text Add to dashboard Cite

Background: To provide an update on the intravitreal use of triamcinolone acetonide. Methods: Review of literature regarding triamcinolone-related research. Results: After the introduction of bevacizumab and ranibizumab into clinical practice, intravitreal triamcinolone has lost its leading position as the drug most often injected intravitreally. Due to its properties as a long-acting steroid, triamcinolone has still been used for various conditions such as diffuse diabetic macular edema, retinal vein occlusions, pseudophakic cystoid macular edema, chronic prephthisical ocular hypotony and uveitis, and in combination with bevacizumab or ranibizumab. The complications of intravitreal triamcinolone therapy include secondary ocular hypertension in about 40% of the eyes injected, cataract and postoperative infectious or noninfectious endophthalmitis. Conclusions: Due to its widespread biological effects as a steroid and due to a relatively large therapeutic window, intravitreal triamcinolone has remained in clinical use for a variety of intraocular disorders, and it may be a promising candidate for intravitreal medical combination therapies.

show abstract

Section: Clinical Studies: Ta In Other Ocular Diseasessupporting

confidence: 52%

Section: Clinical Studies: Ta In Other Ocular Diseasesmentioning

confidence: 99%

Intravitreal Triamcinolone

Tao

Jonas

2010

Ophthalmologica

Self Cite

View full text Add to dashboard Cite

show abstract

“…1,4,5,7,9,10,18,23,24,27,28,[32][33][34][35][36][37][38]40,42 Correspondingly, a recent safety and efficacy study of an intravitreal fluocinolone acetonide sustained delivery device as treatment for cystoid macular oedema in patients with uveitis 13 and other clinical and experimental studies have not shown a toxic effect of intraocular steroids. [53][54][55][56] An elevation of intraocular pressure above 21 mmHg occurring in seven eyes (70%) in the present study was not a major clinical problem.…”

Section: Discussionmentioning

confidence: 99%

“…[31][32][33][34][35][36] In aqueous humour and in silicone oil, respectively, triamcinolone acetonide has been found up to 1.5 years and up to 8 months, respectively, after the intravitreal injection. [37][38][39][40] Systemic and local side effects reported so far include cataract, secondary ocular hypertension, leading in some patients to secondary chronic open-angle glaucoma, [41][42][43] and postinjection infectious endophthalmitis.…”

Section: Introductionmentioning

confidence: 99%

Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide

Jonas

Akkoyun

Kamppeter

et al. 2004

Eye

147

View full text Add to dashboard Cite

Purpose To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity in branch retinal vein occlusion. Methods The prospective comparative nonrandomized clinical interventional study included 28 patients (28 eyes) with branch retinal vein occlusion. The study group consisting of 10 consecutive patients received an intravitreal injection of 20-25 mg of triamcinolone acetonide. The control group including 18 patients did not receive an intravitreal injection. The mean follow-up was 8.774.4 months.

show abstract

“…Indeed, several studies reported the benefits of triamcinolone acetonide intravitreal injections (IVTA) in reducing DME and increasing visual acuity [3][4][5][6], alone or in association with laser treatment, and also like a useful additional tool in the management of neovascular glaucoma [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Neovascular Glaucoma and Diabetic Macular Edema in a Patient with Monolateral Pseudoexfoliative Glaucoma and Type 2 Diabetes: Therapeutic Effects of Two-Sided Intravitreal Triamcinolone Acetonide Treatment

Mutolo¹

2015

AOVS

View full text Add to dashboard Cite

Background: To report on the safety and efficacy of intravitreal injections of triamcinolone acetonide in a patient with diabetic macular edema in the right eye and pseudoexfoliative glaucoma complicated by iris neovessels in the left eye.Case presentation: Two intravitreal injections of triamcinolone acetonide were given (one per eye) in a 75 year-old caucasian male with macular edema in the right eye and neovascular glaucoma in the left eye. Changes in visual acuity, intraocular pressure, ophthalmoscopic examination of the anterior and posterior segment and flicker ERG response were regularly detected during a period of 6 months. Conclusion:Bilateral visual acuity improvement was obtained after each injection and maintained for the whole observation period. Central retinal thickness in the right eye decreased after intravitreal injections of triamcinolone acetonide and remained stable until the last observation 6 months later. Iris neovessels in the left eye disappeared after the injection in the left eye. Flicker ERG implicit time in the right eye improved after intravitreal injections of triamcinolone acetonide, and remained stable in the left eye. No side effects of the treatment were observed. Intraocular pressure in the right eye remained within normal values without any intraocular pression-lowering drug, whereas it showed even some decrease in the left eye, despite the presence of glaucoma.

show abstract

Neovascular glaucoma treated by intravitreal triamcinolone acetonide

Cited by 28 publications

References 7 publications

Intravitreal Triamcinolone

Intravitreal Triamcinolone

Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide

Neovascular Glaucoma and Diabetic Macular Edema in a Patient with Monolateral Pseudoexfoliative Glaucoma and Type 2 Diabetes: Therapeutic Effects of Two-Sided Intravitreal Triamcinolone Acetonide Treatment

Contact Info

Product

Resources

About